The news: During its Q2 2022 earnings call on August 4, Amwell said it will partner with CVS on the retailer’s new Virtual Primary Care service.
Alongside the news: Despite telehealth usage declining overall, Amwell reported a 7% annual increase in revenues, hitting $64.5 million for Q2 2022, up from $60.2 million in Q2 2021.
How we got here: CVS announced in May that it will launch its virtual care platform next year. Aetna plan sponsors and clients of CVS pharmacy benefits manager Caremark will have access to the platform.
Trendspotting: Despite the growth of partnerships with pharmacies, and the rising numbers from Amwell, telehealth use has been dropping overall this year.
What’s next? We’re watching the competition between two virtual care platforms: Amwell’s Converge and Teladoc’s Primary360.
For context, CVS is already working with Teladoc on a virtual care solution, offering it to self-funded employers. So, CVS now has deals with both companies.
Although Teladoc is expanding its Primary360 platform, it posted a steep loss of $3.1 billion in Q2. The race is on to see who will develop stronger relationships with pharma, and with the deep amount of integrations that Amwell Converge offers, Amwell should be well positioned for more pharma deals in primary care.
In the earnings call, Amwell CEO Ido Schoenberg hinted at more integrations to come as its platform will serve as a layer to connect patients, providers, payers, and employers.
Go deeper: Check out our US Telehealth Trends 2022 report.
This article originally appeared in Insider Intelligence's Digital Health Briefing—a daily recap of top stories reshaping the healthcare industry. Subscribe to have more hard-hitting takeaways delivered to your inbox daily.
11 Times SquareNew York, NY 100361-800-405-0844